A once-daily subcutaneous injection of 3.0 mg of liraglutide, along with diet and exercise, is showing promise as an effective weight-management treatment. The industry-supported study, published recently by the New England Journal of Medicine, reported that two-thirds of patients on the injectable glucagonlike peptide-1 receptor (GLP-1) agonist lost at least 5% of their body weight, compared with just more than a quarter of those on placebo. Participants in the 56-week double-blind study did not have type 2 diabetes, but had a body-mass index of at least 30 or slightly less if they had treated or untreated dyslipidemia or hypertension.

« Click here to return to The MTM Review.